NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Transcend Biologics

Transcend Biologics

Private
The Colony, TexasHealthcare & Life Scienceshttps://transcendbiologics.com/

Last Round

M&A

Mar 27, 2026

Est. Valuation

$1.23B

Total Funding Raised

$41.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Transcend Biologics is a medical technology company that develops and distributes platelet-rich plasma (PRP) solutions for medical and veterinary professionals.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

platelet-rich plasmaPRPPRP preparation systemregenerative medicineautologous biologicsveterinary PRPpoint of care devicecell therapysports medicineorthopedicsPRP centrifugemedical consumablesanimal healthsingle-use kitscash-pay procedures

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Transcend Biologics Comparables

Compare Transcend Biologics with similar companies based on industry and business-model similarity.

Transcend Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Transcend Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AMar 27, 2026
Series AFeb 23, 2023
SeedDec 17, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Paul O'Brien

Chief Executive Officer

Executive Team

Transcend Biologics Investors

Notable investors and investment history

Transcend Biologics investors
InvestorRounds
AlleyCorpSeries A, Seed
Emerald Development ManagersSeries A
IntegratedSeries A
Global Founders CapitalSeries A
Alpha Wave GlobalSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 27, 2026

    $700M raised with Otsuka Pharmaceutical

  • Jan 21, 2026

    Monthly visitors increased 39% MoM, reaching 2.7K.

View all signals

Transcend Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Transcend Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Transcend Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersThe Colony, Texas
Employee Range7
Year Founded2021
Last FundingMar 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.